During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

Traditional and new laboratory tools along with advances in AI are outlining a new paradigm in human disease modeling.

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to ...

Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase ...

Felzartamab's mechanism of action designed to deplete the cells that produce ... About Felzartamab Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.